Trial Profile
A Phase 1, Multi-center, Single-masked, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Ophthalmologic Safety and Pharmacodynamics of 300mg Single Doses of Tafenoquine (SB 252263) in Adult Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Tafenoquine (Primary)
- Indications Vivax malaria
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 11 Jun 2019 Pharmacodynamic results published in the Drug Safety.
- 01 Mar 2018 Status changed from active, no longer recruiting to completed.
- 16 Jan 2017 Status changed from recruiting to active, no longer recruiting.